CA-SCIENTIST.COM
Scientist.com, the healthcare industry’s leading marketplace for life science research, announced today the launch of VERIF.i® , a standardized supplier pre-assessment program. Research organizations use VERIF.i to evaluate the facilities, personnel and processes supporting the sourcing of human biological samples and research services involving animals. Supplier pre-assessments improve quality management, reduce costs and reduce risk.
“VERIF.i enables suppliers to differentiate themselves from their peers while also enabling customers to gain valuable, unbiased insight into their procedures and expertise,” stated Matt McLoughlin, Scientist.com's VP of Compliance & Categories. “The program streamlines the proactive assessment of suppliers, reducing costs and saving time.”
On-site assessments are expensive, resource intensive and time consuming for customers and suppliers. Scientist.com developed VERIF.i to provide a new approach to supplier pre-assessments that helps both sides of the market. Independent 3rd party auditors use a customized, industry developed checklist to confirm that a supplier’s facilities, processes and systems meet a customer’s research and regulatory requirements. The pre-assessments help customers select suppliers in an accelerated manner with more confidence and less risk.
“For all projects, our international team of auditors employs quality control measures and follows appropriate SOPs to ensure that our work meets each client’s high standards,” stated Cheri A. Wilczek, President and Founder of ClinAudits. “As an independent, 3rd party auditing and consulting organization, we provide Scientist.com’s client base with an additional layer of due diligence when using VERIF.i pre-assessments to decide which suppliers to work with for their individual organization.”
To learn more about VERIF.i, including how to sign up, visit scientist.com/verifi
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saving time and money, reducing risk and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, the Biotechnology Innovation Organization (BIO) and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised $39 million from 5AM Ventures, Leerink Transformation Partners and Heritage Provider Network among others.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005094/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 08:57:00 CEST | Press release
Almirall’s scientific presence at the 34th EADV congress reflects its broad portfolio of dermatological treatments and patient-centric approach - featuring 44 abstracts, two expert-led symposia on atopic dermatitis and psoriasis, and an interactive booth. Lebrikizumab’s effectiveness in the treatment of moderate-to-severe atopic dermatitis is demonstrated by new real-world evidence, and long-term efficacy and patient well-being data. New real-world data demonstrate tildrakizumab’s effectiveness in the treatment of psoriasis in high-impact areas of the body and across multiple patient groups - particularly elderly patients and those with high disease burden. Almirall’s pipeline progress includes new initial phase 1 data on a developmental treatment for Hidradenitis Suppurativa (HS), LAD191 a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL-1RAP) shows preliminary signs of clinical symptom improvements, and a favourable safety and tolerability profile. Almir
SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 08:50:00 CEST | Press release
During international operations, SES’s high-throughput low-latency Medium Earth Orbit (MEO) managed satcom service provided connectivity to flagship aircraft carrier Charles de Gaulle of the French Carrier Strike Group (GAN) SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliabi
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom